← Human Trials & Peer-Reviewed Studies
Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518
Plain-language guide to PMID 28384065 (2017): randomized controlled trial study of Octreotide in 427 patients.
Key Facts
- PMID
- 28384065
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Yao JC et al. (14 authors)
- DOI
- 10.1200/JCO.2016.70.4072
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Octreotide.
Purpose Treatment options for neuroendocrine tumors (NETs) remain limited.
Why It Was Studied
This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs.
Patients and Methods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group system, enrolled patients with advanced grades 1 and 2 NETs with progressive disease or other poor prognostic features.
Who Took Part
The abstract describes 427 patients taking part.
By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.
Results A total of 427 patients was enrolled, of whom 214 were allocated to bevacizumab and 213 to IFN-α-2b.
How the Study Was Run
In design terms this was a randomized study.
The patients were allocated by chance, so the Octreotide group and the comparison group should start out alike.
What Was Measured
This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs.
The primary end point was centrally assessed PFS.
The subject headings attached to it are Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoid Tumor, Disease-Free Survival, Drug Delivery Systems, Interferon alpha-2 and Interferon-alpha.
What This Means in Plain Language
The paper is a randomized study of Octreotide in 427 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2017 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.
More context: the Octreotide compound page, all human trials.
Our Notes on the Compound
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.